Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

作     者：Javier Cortés 

作者机构：From the International Breast Cancer Center Quirónsalud Group Barcelona the Scientific Department Medica Scientia Innovation Research Valencia and the Department of Medicine Faculty of Biomedical and Health Sciences Universidad Europea de Madrid Madrid — all in Spain (J. Cortés) Asan Medical Center University of Ulsan College of Medicine Ulsan (S.-B.K.) Seoul National University Hospital Cancer Research Institute (S.-A.I.) and Seoul National University Bundang Hospital (J.H.K.) Seoul National University College of Medicine and Samsung Medical Center (Y.H.P.) Seoul and Severance Hospital Yonsei University Yonsei (M.H.K.) — all in South Korea the Department of Oncology National Cheng Kung University Hospital College of Medicine National Cheng Kung University Tainan (W.-P.C.) and the Department of Surgery Taipei Veterans General Hospital College of Medicine National Yang-Ming Chiao Tung University (L.-M.T.) Koo Foundation Sun Yat-Sen Cancer Center (C.-F.C.) and National Taiwan University Hospital and National Taiwan University College of Medicine (C.-S.H.) Taipei — all in Taiwan Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária (R.H.) and Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira (V.P.) São Paulo and Hospital Nossa Senhora da Conceição Porto Alegre (J.L.P.) — all in Brazil Aichi Cancer Center Hospital Aichi Japan (H.I.) Sarah Cannon Research Institute Tennessee Oncology Nashville (E.H.) the Department of Oncology and Hematology–Oncology University of Milan and the Division of Early Drug Development European Institute of Oncology Istituto di Ricovero e Cura a Carattere Scientifico — both in Milan (G.C.) the Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing (B.X.) the University of Hong Kong Hong Kong (J.W.Y.C.) Daiichi Sankyo Basking Ridge NJ (C.L. Y.L. J. Cathcart E.B.) AstraZeneca Gaithersburg MD (S.V.) and the David Geffen School of Medicine and Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles (S.A.H.).Dr. Cortés can be contacted at [email protected] or at the International Breast Cancer Center Marquesa de Vilallonga 12 08017 Barcelona Spain. A list of investigators in the DESTINY-Breast03 trial is provided in the Supplementary Appendix available at NEJM.org. 

出 版 物：《四川生理科学杂志》 (Sichuan Journal of Physiological Sciences)

年 卷 期：2022年第44卷第2期

页      面：374-374页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：AstraZeneca, (NCT03529110) AstraZeneca Daiichi-Sankyo 

主　　题：Trastuzumab HER2 Breast 

摘      要：Background:Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2(HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies and a ***:We conducted a phase 3,multicenter,open-label,randomized trial to compare the efficacy and safety of trastuzumab deruxtecan(a HER2 antibody-drug conjugate)with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a *** primary end point was progression-free survival(as determined by blinded independent central review);secondary end points included overall survival,objective response,and safety.